Form 4: VenBio Global Strategic Fund III, L.P. Reports Ownership Changes in Artiva Biotherapeutics, Inc. Following IPO

VenBio Global Strategic Fund III, L.P. reports conversion of preferred stock and SAFE agreements into common stock following Artiva Biotherapeutics' IPO.

Summary

• VenBio Global Strategic Fund III, L.P., along with related entities and directors, filed a Form 4 detailing changes in beneficial ownership of Artiva Biotherapeutics, Inc. (ARTV) common stock on July 22, 2024.
• The filing reflects the conversion of Series A and Series B Preferred Stock into common stock on a one-for-one basis upon the closing of Artiva Biotherapeutics' initial public offering (IPO).
• Additionally, outstanding simple agreements for future equity (SAFE) were converted into common stock at a 15% discount to the $12 IPO price, resulting in a conversion price of $10.20 per share.
• The total common stock beneficially owned following the reported transactions is 1,936,637 shares.
• The reporting parties include venBio Global Strategic Fund III, L.P., venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd., and directors Robert Adelman and Corey Goodman.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard post-IPO transactions and indicates continued significant ownership by a major investor, suggesting confidence in the company's prospects.

Positives

• The conversion of preferred stock and SAFE agreements into common stock indicates confidence in Artiva Biotherapeutics' future prospects following its IPO.
• VenBio's continued significant ownership stake suggests a long-term investment strategy.

Future Outlook

The document does not contain specific forward-looking statements, but the conversion of preferred stock and SAFE agreements suggests a positive outlook from VenBio regarding Artiva Biotherapeutics' future performance.

Industry Context

Form 4 filings are standard practice following an IPO and provide transparency regarding significant ownership changes. VenBio's actions are typical for venture capital firms following the public listing of a portfolio company.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for individuals or entities holding more than 10% of a company's shares, aligning with SEC regulations.
• The conversion of preferred stock and SAFE agreements into common stock upon an IPO is a common practice in the venture capital industry, ensuring alignment of interests between early investors and public shareholders.
• VenBio's continued significant ownership stake after the IPO is comparable to other venture capital firms that maintain a substantial position in their portfolio companies post-IPO, such as Kleiner Perkins in Beyond Meat or Sequoia Capital in Zoom.

Stakeholder Impact

• The conversion of preferred stock and SAFE agreements into common stock could impact shareholders by increasing the number of outstanding shares.
• The continued significant ownership by VenBio may reassure investors about the company's long-term prospects.

Key Dates